2009
DOI: 10.1186/1471-2210-9-11
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of molecular descriptors for antitumor drugs with respect to noncovalent binding to DNA and antiproliferative activity

Abstract: Background: Small molecules that bind reversibly to DNA are among the antitumor drugs currently used in chemotherapy. In the pursuit of a more rational approach to cancer chemotherapy based upon these molecules, it is necessary to exploit the interdependency between DNA-binding affinity, sequence selectivity and cytotoxicity. For drugs binding noncovalently to DNA, it is worth exploring whether molecular descriptors, such as their molecular weight or the number of potential hydrogen acceptors/donors, can accou… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
9
0

Year Published

2010
2010
2019
2019

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 18 publications
(9 citation statements)
references
References 39 publications
0
9
0
Order By: Relevance
“…DNA-binding molecules or intercalators represent a class of clinically useful drugs [2]. Most of these bind non-covalently to the DNA along the grooves or intercalate at specific sequences [3].…”
Section: Introductionmentioning
confidence: 99%
“…DNA-binding molecules or intercalators represent a class of clinically useful drugs [2]. Most of these bind non-covalently to the DNA along the grooves or intercalate at specific sequences [3].…”
Section: Introductionmentioning
confidence: 99%
“…Despite their intricacies, physicochemical properties of probes can be defined numerically through their structural information, so-called descriptors. Descriptors have long been exploited in computational quantitative structure activity relationship study, for instance, to predict aqueous solubility and permeability of drugs 6 7 , binding affinities of antitumor drugs 8 9 and also cellular uptake and localization of fluorescent probes 10 11 .…”
mentioning
confidence: 99%
“…It is well known that most of antitumor drugs are usually used in clinical trials owing to the high correlation between some of binding DNA and their cytoxicity (Portugal 2009). Roughly, 24 antiangiogenic drugs are currently undergoing evaluation in phase I, II, or III clinical trials.…”
Section: Discussionmentioning
confidence: 99%